SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?Decision Resources
May 20, 2009
37 Pages - SKU: DECR2272770
More Biopharmaceuticals reports by Decision Resources
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? by Decision Resources
The moderate to severe RA population represents a sizable target for agents acting on the immune system. However, the barriers to entry are ...
U.S. Payer and Prescriber Attitudes Toward Novel Oral, Topical, and Biologic Emerging Agents in the Psoriasis Market: Implications for Market Access by Decision Resources
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-a) inhibitors ...
How Will U.S. Payers and Prescribers Determine the Success of New Biologics and Oral Entrants and Currently Marketed Biologics in Psoriatic Arthritis and Axial Spondyloarthritis? by Decision Resources
This U.S. Physician & Payer Forum report explores payer and physician dynamics that affect prescribing practices for psoriatic arthritis (PsA) and axial spondyloarthritis ...
Innovative R&D and Dealmaking Opportunities: Oncology Biologics: Novel Therapeutic Antibodies, Proteins, and Peptides by Decision ResourcesSee all reports like this >>
The market for oncology biologics is lucrative; growth in this sector will outpace the overall oncology market, resulting in an increased share of ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
- Biologic Therapeutic Drugs: Technologies and Global Markets
- Biologic Imaging Reagents: Technologies and Global Markets
- Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends
- How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis?